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Alongside cancer cells, tumours exhibit a complex stroma containing a reper-
toire of cells, matrix molecules and soluble factors that actively crosstalk
between each other. Recognition of this multifaceted concept of the tumour
microenvironment (TME) calls for authentic TME mimetics to study cancer
in vitro. Traditionally, tumourigenesis has been investigated in non-human,
three-dimensional rat type I collagen containing organotypic discs or by
means of mouse sarcoma-derived gel, such as Matrigelw. However, the mol-
ecular compositions of these simplified assays do not properly simulate
human TME. Here, we review the main properties and benefits of using
human leiomyoma discs and their matrix Myogel for in vitro assays.
Myoma discs are practical for investigating the invasion of cancer cells, as
are cocultures of cancer and stromal cells in a stiff, hypoxic TME mimetic.
Myoma discs contain soluble factors andmatrix molecules commonly present
in neoplastic stroma. In Transwell, IncuCyte, spheroid and sandwich assays,
cancer cells move faster and form larger colonies inMyogel than inMatrigelw.
Additionally, Myogel can replace Matrigelw in hanging-drop and tube-
formation assays. Myogel also suits three-dimensional drug testing and
extracellular vesicle interactions. To conclude, we describe the application
of our myoma-derived matrices in 3D in vitro cancer assays.
This article is part of the discussion meeting issue ‘Extracellular vesicles
and the tumour microenvironment’.1. Introduction
The migration and invasion of cancer cells into adjacent tissue are important
initial steps in carcinogenesis, which can lead to metastasis formation at second-
ary sites [1]. Solid tumours are generally considered invasive once they begin to
penetrate the surrounding extracellular matrix (ECM) and multiple layers of
mesenchyme [2]. The transformed epithelial cells may invade via the epi-
thelial–mesenchymal transition, where cancer cells gain multiple attributes
enabling invasion and metastases. Cancer cell invasion may arise individually
(elongated-mesenchymal, rounded amoeboid and spike-mediated) or collec-
tively (multicellular streaming, tumour budding and collective invasion) [3,4].
The surrounding neoplastic stroma of cancer cells—that is, the tumour
microenvironment (TME)—is an active player in the multistep process of the
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cancer cells and TME leads to several changes in the struc-
ture and protein content of solid tumours. All TME
compounds—including cells, ECM, soluble factors and
extracellular vesicles (EVs)—collectively with cancer cells
are crucial in affecting the complex processes of cancer
invasion and metastases.
In experimental cell biology, cell migration and invasion
represent distinct phenomena. Migration is the directed
movement of cells that do not pass through obstructive bar-
riers, whereas invasion necessitates the destruction of
barriers in order to pass through them and thus by necessity
is accompanied by ECM remodelling [5].
Here, we first briefly summarize the main carcinoma TME
components including cancer-associated fibroblasts (CAFs),
immune cells, blood vessels, matrix molecules, proteases
and EVs. Second, we describe the properties of our human
uterus leiomyoma tissue–derived matrices, myoma discs
and Myogel. Finally, we provide examples of their appli-
cation in three-dimensional (3D) cancer migration and
invasion assays as well as in cancer drug testing.
(a) Cancer-associated fibroblasts
CAFs are found in the TME of most solid tumours. While
these cells were recognized long ago, their origin is not yet
definitively known. Several theories were proposed and sev-
eral types of cells were suggested as the origin of CAFs,
including resident fibroblasts, mesenchymal stem cells and
malignant epithelial cells [6–9]. Some suggested that CAFs
represent the leading cells in tumour invasion allowing
cancer cells to follow [10]. As such, CAFs play a primary
role in tumour development, growth and metastasis [11]. Fur-
thermore, their presence predicts poor survival in mobile
tongue carcinoma, especially when located around tumour
islands [12,13]. However, CAFs are not always related to a
poor prognosis, at least not in pancreatic cancers [14].
Several markers can be used to identify CAFs, such as
a-smooth muscle actin (SMA), fibroblast-specific protein 1,
fibroblast activation protein (FAP), desmin, platelet-derived
growth factor b (PDGF-b) receptor and fibroblast growth
factor (FGF) [15,16]. Some of these CAF-related markers,
such as aSMA, FAP and the PDGF-b receptor, have been
associated with poor prognosis for colorectal and pancreatic
cancers [15]. In addition, CAFs are known to support
cancer metastasis [17]. Interestingly, CAFs are also found in
the lymph nodes in secondary tumours associated with oral
carcinomas. Yet it remains unclear whether those CAFs
accompany cancer cells or if they are differentiated in situ at
the lymph node [12].
(b) Immune cells
Large amounts of inflammatory cells are located within a
tumour, which are closely related to tumour progression or
suppression [18]. Inflammation within the tumour can be
divided into acute and chronic conditions, where, in general,
the former is known to decrease cancer risk and the latter
increases it [19]. Recent advances in tumour immunity
could clearly distinguish two types of tumour-infiltrating
immune cells: the tumour-associated myeloid cells, mainly
representing innate immunity, and those usually working
in favour of tumour progression [20,21]. On the other side,
in patients with high T cells, representing adaptive immunity,infiltrated tumours show better prognosis [22,23]. Interest-
ingly, in oral tongue cancer the high infiltration of CD163þ
Foxp3þ CD80þ cells altogether was associated with high
recurrence rate [24]. Inflammation participates in every
stage of tumour development by secreting cytokines, che-
mokines, growth factors, prostaglandins and reactive
oxygen and nitrogen species. Tumour progression partly
depends on the balance between anti-tumorigenic and
pro-tumorigenic immune and inflammatory factors. As a
result of their importance in TME, immune cells were used
to develop a new strategy for cancer treatment called
immunotherapy [25].
Cancer immunotherapy research is rapidly growing and
attracting wide interest. Based on boosting the patient’s
immune system to eliminate cancer cells, immunotherapy
surpasses conventional chemotherapy in its specificity and
improves therapy-related morbidities. The mechanism of
immunotherapy depends on the immune system, which
ranges from boosting the entire immune system to directing
specific immune cells towards the tumour. Several immu-
notherapies are already in the clinical-trial stage and some
are already used clinically. Between these immunotherapies,
immune checkpoint inhibitors against CTL4, PD-1 and PD-
L1 were found to be the most successful candidates [26].
Advances in immunotherapy research have already greatly
improved the management of many cancer types. Cancer
responses to immunotherapies remain inconsistent, from
highly effective in some patients to completely ineffective in
others [27,28]. Thus, we need to better understand the inter-
action between cancer and immune cells as a part of TME,
whereby additional in vitro and in vivo studies are needed.
(c) Angiogenesis
Tumour progression requires a constant supply of nutrition
and oxygen. Therefore, in theory, neo-angiogenesis—the for-
mation of new capillaries—is an essential process for tumour
growth and metastasis [29]. Angiogenesis depends on a bal-
ance between promoters and inhibitors [30]. TME serves as a
storage space for factors that affect angiogenesis. Among these,
vascular endothelial growth factors play a key role in tumour
angiogenesis [31]. In turn, VEGF affects several functions,
including inducing angiogenesis, stimulating proliferation,
acting as a survival factor and preventing endothelial cell
apoptosis, regulating vascular permeability, promoting
chronic inflammation and healing wounds [31,32].
Tumour blood vessels differ from physiological angiogen-
esis, having more loosely attached pericytes that express
desmin and a-SMA [33]. Tumour neovascularisation remains
heterogeneous and includes capillary sprouting, convoluted
and excessive vessel branching, distorted and enlarged
vessels, erratic blood flow, microhaemorrhaging, leakiness
and abnormal levels of endothelial cell proliferation, and
apoptosis [3]. These features of tumour blood vessels explain
why tumours are often hypoxic despite being highly vascu-
larized [34]. In addition to VEGF, also several other factors
are suggested to induce tumour angiogenesis, such as trans-
forming growth factor (TGF)-a, FGF-3 and hepatocyte
growth factor (HGF) [35].
(d) Matrix molecules and proteases
The composition of the TME matrix greatly affects the phys-
ical, biochemical and biomechanical properties regulating
Figure 1. GFP-transfected HSC-3 squamous cell carcinoma cell line invading
in 3D Myoma disc.
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between cancers, but is primarily composed of structural pro-
teins and soluble factors. Structural molecules include
various collagens, fibronectin, laminins, proteoglycans, hya-
luronic acid and tenascin. The soluble components include,
for example, cytokines, growth factors and cryptic molecules
liberated from the TME matrix [36]. Many of these com-
ponents are synthesized by fibroblasts or released by
proteases secreted by CAFs or cancer cells. Indeed, tumouri-
genesis overturns ECM, liberating many molecules that
support cancer cell invasion and proliferation.
Matrix metalloproteases (MMPs) consist of a family of 24
endopeptidases that are overexpressed in several tumours.
MMPs are the main modifiers of TME because they can
hydrolyze most of the primary matrix macromolecules
[37,38]. Most MMPs are pro-angiogenic, pro-invasive and
pro-metastatic due to their ability to modulate ECM, thus
allowing cancer cells to penetrate into the surrounding
tissue. MMPs also liberate chemokines and growth factors
from ECM affecting cancer progression. However, some,
such as MMP-8, also play a protective role because they can
liberate anti-tumorigenic molecules inhibiting the spread of
cancer [39]. MMPs are regulated via the activation and in-
hibition of the tissue inhibitors of metalloproteinases
(TIMPs). The net proteolytic activity of MMPs depends on
the molecular balance between MMPs and TIMPs [39–41].
Integrins are cell surface receptors that meditate com-
munication between cells and TME. They promote tumour
angiogenesis, tumour cell proliferation and metastasis for-
mation [42]. Integrins promote cancer growth in several
ways. For example, VEGF can activate integrins leading to
angiogenesis, or integrins can increase migration and invasion
by activating proteases to remodel TME [43].(e) Extracellular vesicles
Despite the importance of soluble proteins in the modulation
of the intercellular communication at primary and secondary
tumour sites, EVs have emerged as key players in the
crosstalk between cancer and TME cells [44,45]. EVs are a het-
erogeneous population of cell-derived vesicles enclosed by a
lipid bilayer ranging in size from 30 to 2000 nm, and are
classified based on their cellular origin, biological function
or biogenesis [46,47]. EVs contain bioactive molecules, such
as nucleic acids (DNA, mRNA, microRNA and other non-
coding RNAs), proteins (receptors, transcription factors,
enzymes and ECM proteins) and lipids, all of which can
redirect the function of the recipient cell [48].
EVs preserve the bioactivity of their molecular cargo and
can be readily isolated from multiple biological fluids (such
as urine, serum, plasma, pleural effusion and saliva),
suggesting that these particles may constitute potential bio-
markers for the real-time assessment of cancer progression
[49]. Differential ultracentrifugation stands as a conventional
and the most widely used method to isolate different vesicles,
but no consensus regarding a ‘gold standard’ method for the
isolation or purification of EVs currently exists. The most effi-
cient method depends primarily on the specific question
asked in experiments as well as the downstream application
of the particular EVs [50].
In order to elicit functional effects, EVs dock to target cells
and initiate signalling events either at the cell surface or
within cells. In either case, EVs are capable of promotingphenotypic changes in recipient cells depending on their
cargo [51]. Specifically, in TME EVs mediate heterotypic
interactions between stromal and cancer cells supporting
fundamental cancer hallmarks, such as evading growth
suppressors, resisting cell apoptosis, sustaining prolifera-
tive signalling, evading immune destruction and inducing
migration, invasion and angiogenesis [52].
ECM remodelling is generally thought to promote invasive
tumour phenotypes, including oral tongue cancer [53–55].
Secreted tumour EVs coated with fibronectin promote nascent
adhesion assembly and increase cell motility [56]. Interestingly,
we recently showed that a high concentration of fibronectin in
oral tongue squamous cell carcinoma (OTSCC) TME associated
with a poor prognosis, especially with early stage tumours,
indicating a pro-carcinogenic role for TME fibronectin [57].
The mutual interplay between cancer cells and fibroblasts is
thus crucial for cancer progression and EVs from cells actively
participating in this process [58]. Furthermore, TGF-b associ-
ated with tumour EVs can trigger fibroblast differentiation
into CAFs. Additionally, the ECM metalloproteinase inducer
(EMMPRIN) found in the microvesicles shed by tumour cells
can enhance the production of MMPs in fibroblasts, enabling
tumour invasion and metastasis [59]. Similarly, recent work
within our group demonstrated that EVs derived from CAFs
can increase the invasiveness of tumours in oral squamous
and colorectal carcinoma cell lines (MR Dourado 2016, unpub-
lished data). By contrast, endothelial cells stimulated by VEGF
and FGF-2 release EVs containing MMPs that initiate the pro-
teolysis necessary for tumour invasion and uninhibited
angiogenesis [60].2. Three-dimensional in vitro invasion assays
using myoma discs
(a) Properties of myoma tissue discs
Ten years ago, we discovered that human uterus leiomyoma
tumour–derived discs excellently mimic native TME for 3D
cancer invasion assays ([61], figure 1). Unlike in myoma, no
invasion of human oral tongue squamous cell carcinoma
(HSC-3) cells was seen in a similar 3D set-up of discs pre-
pared from a normal pig tongue or a human heart [55].
From an average-size tumour, more than 100 ready-to-use
(a)
(c)
(b)
Figure 2. Oral tongue highly invasive HSC-3 squamous cell carcinoma cell line shows similar invading pattern to carcinoma cells in vivo. Pancytokeratin staining of
patient section of an oral tongue squamous cell carcinoma (a), HSC-3 cell line in organotypic type I collagen and fibroblast disc section (b), and in Myoma disc (c).
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parison to similarly sized 3D invasion discs made from rat
tail type I collagen [62] with or without EHS mouse sar-
coma-derivative Matrigelw, myoma discs provide a natural,
complete human TME matrix. As an aggressive OTSCC cell
line, HSC-3 cells penetrate seven times more profoundly in
myoma than in collagen discs ([61], figure 2). Various solid
cancer cell lines tested in myoma show that, in general, the
more invasive the cells are in vivo, the deeper they invade
in myoma discs (table 1). Instead, the less invasive OTSCC
cells began to secrete keratin, unlike the more aggressive
cell line (figure 3). Within myoma, the invasion patterns of
OTSCC mimic the mesenchymal, collective or budding
types seen in in vivo patient tissue sections. Some carcinoma
cells within myoma discs demonstrate an epithelial-to-
mesenchymal transition positive for both mesenchymal
and epithelial cell markers [61]. In electron microscopy
analyses, HSC-3 cells on top of myoma discs produce base-
ment membrane (BM) structures, whereas deeper invading
cells protrude invadopodia surrounded by broken BM
fragments [55].
Myoma discs comprise ECM structural proteins, such as
type I, III and IV collagens and laminins [61]. TME cells,
including fibroblasts, endothelial and smooth muscle cells,
as well as CD68þ and CD45þ inflammatory cells, are also pre-
sent [61]. Yet during the 3D culture procedure they all remain
non-vital [71]. Depending on the myoma, the number of
ECM molecules varies. After analysing myoma from more
than 150 patients, we may conclude that the greater the
amount of tenascin-C within the myoma discs, the deeper
the cancer cells invade [55]. Interestingly, tenascin-C,
especially in TME, serves as a marker for a poor prognosis
in several solid cancers, including OTSCC [57]. As a result
for this heterogeneity with the Myoma discs, all the exper-
iments should be done using one single batch of Myoma to
avoid such variations within the experiments. Similar vari-
ations are also known when using Matrigel and other
animal-based ECM [72,73].Native myoma discs are hypoxic [63]. Hypoxia in solid
tumours induces invasion and affects, for instance, cell
metabolism and angiogenesis [74]. When myoma discs
are effectively rinsed, the soluble factors, including binding
proteins, growth factor receptors and growth factors, are
released. Some of these growth factors include HGF and
fibroblast growth factor 2 (FGF2) and transforming
growth factor beta (TGF-b) 1 and 2, which are known to
affect cell motility [55]. Other soluble molecules in rinsing
include MMP-11, lysyl oxidase-1 (LOX-1) and carbonic
anhydrase IX (CA-9), all of which have been shown to
facilitate cancer invasion in vivo [63]. Interestingly, intact
myoma discs induced the upregulation of the urokinase
plasminogen activator receptor (uPAR), which at the
invasive tumour front is indicative of a poor prognosis
in oral cancer [74]. In rinsed myoma, the invasion depth
is significantly diminished compared with that in the corre-
sponding native disc. However, in rinsed myoma, the type
III collagen degradation, measured using a radioimmuno-
assay of a type III collagen fragment carboxy-terminal
telopeptide in a myoma culture medium, increases. This
suggests a greater need for the enzymatic degradation of
collagen in order for cancer cells to invade cancer cells
in rinsed rather than in native discs [63]. This shift in the
invasion mechanism is also seen in lyophilized and rehy-
drated myoma discs. The invasion depth remains the
same, although type III collagen degradation is higher in
lyophilized discs compared with the corresponding
native discs [55]. This system is suitable for measuring
the invasion of cancer cells that degrade enzymatically
myoma collagen, such as OTSCC cell lines. In the case of
melanoma cells, which use non-enzymatic invasion mech-
anism in myoma, the radioimmunoassay method is not
suitable (figure 3c).
Myoma discs are used to compare the invasion of par-
ental and transduced cell lines, such as MMP-8, endostatin,
urokinase plasminogen activator receptor (uPAR) and tryp-
sin-2 overexpressed, or cathepsin K, snail, miRNA-498 and
Table 1. Cell lines tested in myoma discs and Myogel using scratch wound assay. The invasiveness of various cell lines is marked using a scale from – (non-
invading) to 111 (highly invading). UD, unpublished data, LE, locally established primary cell lines.
cell line tissue of origin
invasiveness
in myoma
disc
faster in Myogel versus Matrigelw
(unpublished data)
reference
and
additional
dataIncuCyte Transwell
HSC-3 tongue squamous cell carcinoma 111* Myogel Myogel [61]*
SCC-25 tongue squamous cell carcinoma 11* Myogel Myogel [55]*
SCC-15 tongue squamous cell carcinoma 1* [55]*
SAS tongue squamous cell carcinoma 111* Myogel [53]*
UT-SCC-43 tongue squamous cell carcinoma 1* [63]*
DOK dysplastic oral keratinocytes 1/2* [61]*
ODA* HPV 16 immortalized mucosal keratinocytes Myogel [64]*
HMK* immortalized gingival keratinocytes 1** Myogel [65]*, UD**
PE/CA-PJ15 neoplastic oral keratinocytes 1* UD*
UK-1 oro-pharyngeal keratinocytes 1* [61]*
MDA-MB-231 mammary gland, breast 11* Myogel ¼ Matrigelw [61]*
MDA-MB-435 melanoma 1* UD*
Bowes melanoma 111* Myogel [61]*
G361 melanoma 11* [61]*
HT1080 ﬁbrosarcoma 1* Matrigelw UD*
HaCat human keratinocytes 1/2* Myogel [66]*
UT-MUC-1 mucoepidermoid carcinoma 11* [67]*
SK-MES-1 lung squamous cell carcinoma 111 * [68]*
SK-LU-1 lung adenocarcinoma 1* [68]*
HuH-7 hepatocellular carcinoma 1* UD*
Mahlavu hepatocellular carcinoma 11* UD*
HCT-11 colon adenocarcinoma 11* UD*
Colo-741 colon adenocarcinoma 111* UD*
BEAS-2B non-malignant bronchial cells 11* [68]*
MSCs mesenchymal stem cells 1/2* [69]*
JEG-3 choriocarcinoma cells 1* [70]*
Pa01 liver ductal adenocarcinoma Myogel
Pa02c liver ductal adenocarcinoma Myogel Myogel
Pa03c liver ductal adenocarcinoma Myogel Myogel
Pa04c liver ductal adenocarcinoma no invasion Myogel
ASC* adipocyte stem cells Myogel ¼ Matrigelw *LE
IGF* gingival ﬁbroblasts Myogel ¼ Matrigelw *LE
CAF* oral carcinoma–associated ﬁbroblasts Myogel / Not tested
in Matrigelw
*LE
MEK* high-grade mucoepidermoid carcinoma (1)** No invasion *LE **UD
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Similarly, several compounds have been studied for their
effects on invasion. Specifically, we investigated aptamers
against heparanase, TLR antagonists, TLR ligands and
MMP inhibitor GM6001 [61,67,78–80]. We also used myoma
disc invasion assays to test monoclonal antibodies against
chemokine CCL5, and the drug b-aminoproprionitrile,
which inhibits lysyl oxidase [53,63].(b) Cocultures for carcinoma and cancer-associated
fibroblasts or inflammatory cells in myoma discs
It is quite obvious that coculturing mesenchymal cells, such
as CAFs, and immune cells together with cancer cells in a
two-dimensional (2D) setting is far from truly simulating
the real interaction between these cells. This is due to several
factors, such as the omission of native ECM, different
SCC-15HSC-3
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Figure 3. Cancer cells behave differently in Myoma disc. Highly invasive HSC-3 squamous cell carcinoma cell line invades deeply and covering a large invasion area
(a), whereas less-invading SCC-15 shows less-invasive behaviour and forms a keratin layer (b). Degradation of type III collagen measured from the culture media of
HSC-3 cell line (three separate experiments using myoma batches from three patients) and two different invasive melanoma cell lines (Bowes and G361; three
separate experiments each), (c).
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immune cells.
In order to develop coculturing techniques, the Trans-
well technique was developed to provide a barrier
between different cell lines. Transwell was first introduced
in 1989 by Repesh, and primarily used initially to study
cancer cell invasion [81]. Later, Transwell was applied to
coculture cancer cells with other types of cells, including
fibroblasts and immune cells. With the introduction of
Matrigelw and other synthesised matrices, researchers
began to shift from 2D towards 3D cell cultures. To some
extent, these matrices provided ECM to cells, but the pro-
blem of the missing human ECM–based matrix with
tumour features remained unsolved.
In order to overcome the lack of human-based ECM,
we developed a coculture system using human myoma
tumour discs ([61], see above). This system was first used to
coculture OTSCC with bone marrow mesenchymal stem cells
(BMMSC) [53], fibroblasts [82] and macrophages [83]. Adding
OTSCC together with either BMMSC or tumour-related macro-
phages (M2) stimulated from THP-1 cells induced carcinoma
cell invasion, unlike normal fibroblast and inflammation-
associated M1 macrophages, which reduced invasion when
compared with OTSCC cultures [53,83].
Subsequently, we further developed the system to cocul-
ture OTSCC and non-adherent immune cells. The system is
based on culturing cancer cells on top of the myoma discs
and adding the immune cells (with or without stimulants)
to the bottom of the discs. This system enable us not only
to study the effect of the immune cells on cancer cells, but
also to study the recruitment of the immune cells towards
cancer cells [84]. This system is efficient, but also faces the
problem of missing circulation for the immune cells.3. Myogel preparation and properties
The human uterus leiomyoma tumour–derived matrix
Myogel is prepared using a method similar to that for the
production of Engelbreth–Holm–Swarm (EHS) mouse
sarcoma–derived commercial products, such as Matrigelw,
ECMatrixTM, Cultrexw, BMEw or Geltrexw. Myoma tissue is
ground to a powder, suspended in a sodium chloride
buffer and, after centrifugation, the pellet is homogenized
in the same buffer followed by protein concentration
measurement. Only about one-third of proteins in Myogel
are similar to those in Matrigelw. The same proteins in both
include, for example, laminin, type IV collagen, nidogen,
heparan sulfate proteoglycans and epidermal growth factor.
Unlike Myogel, Matrigelw contains entactin, whereas tenas-
cin-C, an important component in several tumour matrices,
is present only in Myogel [55,85]. Myogel has both latent
and active forms of MMP-2, whereas Matrigelw contains
both gelatinases MMP-2 and MMP-9.
Commercial products prepared from either human tissue or
cocultured human cells, such as skeletal muscle Myogel [86],
amnion tissue extract [87] and a fibroblast–keratinocyte cocul-
ture matrix are available, but these all mimic normal ECM.
None are derived from tumour tissue ECM. In cell culture con-
ditions, the pH of Myogel remains neutral and stable compared
with Matrigelw which is more acidic. OTSCC cells (HSC-3)
adhere better on top of BM-mimicking Matrigelw compared
with the top of TME-mimicking Myogel; however, the
migration of those cells on top of Myogel is faster compared
with the top of Matrigelw [85]. Compared with plastic, HSC-3
cells on top of Myogel changed the expression of 1.4% of the
genes, specifically those related to intracellular organelle,
cytoskeleton organisation and biogenesis [85].
Myogel Matrigel
Figure 4. HSC-3 cells are invading faster in Myogel than in Matrigelw in IncuCyte Zoom system (video).
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of the human cancer cell expression profile and movement in
3D in vitro conditions.
In the following sections, we describe Myogel use in var-
ious experiments, such as Transwell invasion, scratch assay,
spheroid (hanging-drop and round-bottom ULA-plate assay)
and sandwich assays, as well as tube formation assays.
Additionally, Myogel has been used in high-throughput
cancer drug testing.
(a) Cancer invasion assays using Myogel
In vitro invasion assays quantify cells invading through struc-
tures such as basement membrane equivalents, reconstituted
collagen gels or more complex materials [88]. By coating the
porous filter with ECM components, the Transwell system
suitably tests invasion. In both cases, either the invaded or
migrated cells are assessed by counting the cells that pene-
trate the insert, either through visual counting after staining
with dye or fluorescence after lysing invading or migrating
fluorescently labelled cells [5,89]. We showed that several
cancer cell lines invade more efficiently through Transwell
coated with Myogel than when coated with Matrigelw [85]
(table 1). The same system can also be used to study EVs in
cancer migration and invasion, in direct contact with cancer
cells and using a coculture method.
The IncuCytew system is a platform that allows real-time
imaging of vertical and horizontal cell migration and inva-
sion, using either label-free or dual-colour fluorescence to
study specific cell populations in coculture. The traditional
scratch wound healing assay can be performed using a
special Image Lock 96-well plate using the WoundMakerTM
on a confluent cell monolayer creating a uniform wound
area along the wells, allowing measurement of cell movement
into the wound. Coating of the plates with, for instance, col-
lagen I, collagen IV, fibronectin, Matrigelw or Myogel prior to
cell seeding allows us to study migration on differentsubstrates [89]. In doing so, the differential biology of cell
migration and invasion can be explored within the same
plate. After creating the wound and washing to remove
dead cells and debris, a biomatrix can be added on top of
the wounded cell monolayer, and the horizontal cell invasion
into the wound can be monitored. When working with EVs
or for drugs testing, the compound/vesicles can be added
straight into the medium for migration and invasion or into
the biomatrix in the invasion assay. Results are then calcu-
lated based on the speed of wound closure. Using zooming
tools, we can monitor the morphological changes of the
cells during the movement process. This platform has a
special 96-well plate resembling the Transwell system to
assess chemotactic migration and invasion. Based on a simi-
lar idea, the well has two chambers separated by a porous
membrane. The imaging system allows for the real-time
monitoring of vertically invading (through a biomatrix and
membrane) and migrating cells.
Similar to the Transwell assay, several cancer cell lines
invade faster within Myogel than within Matrigelw in the
IncuCytew system using scratch wound assay (figures 4 and
5 and table 1).
(b) Spheroid and sandwich assays using Myogel
Cells can create aggregates—spheroids—which are used for
measuring molecular or biomechanical properties. In hang-
ing-drop spheroids, small droplets of cells are first
embedded within various matrices, such as type I collagen,
or a mixture of Matrigelw and type I collagen or Myogel
and type I collagen. Cell suspension in matrix drops
is placed at the centre of each compartment, and, after a
short incubation, the plate is inverted. A confocal fluor-
escence microscope allows for time-lapse imaging. For
fluorescent detection, the cells are either transfected with len-
tiviral particles (nuclear or cytoplasmic) or stained using a
lipophilic-membrane stain that diffuses laterally. Different
MDA-MB-231
HSC-3
HSC-3 GFP
Pa01c
Pa02c
Pa03c
Pa04c
Myogel Matrigel
migration invasion invasion migration
1 2 3 4 5 6 7 8 9 10 11 12
Figure 5. Cancer cells invade differently in Myogel compared with Matrigelw. Migration and invasion of different cancer cell types were tested in Myogel and
Matrigelw using IncuCyte Zoom system. (See the cell lines table 1.)
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cell shape, are analysed using image analysis software.
We have shown that the invasion speed of HSC-3 cells was
fastest in a Myogel–collagen compared with only collagen
or Matrigelw–collagen matrices in this hanging-drop assay.
In a round-bottom well ULA plate assay [90], analysing
MRC-5 fibroblasts, pancreas cancer (Patu 8988T) cells and
their cocultures both fibroblasts and cancer cells grew signifi-
cantly larger in Myogel than in Matrigelw. However, the sizes
of the cocultures grown in either matrix remained the same
(R Chopra, 2016, unpublished data).
In a sandwich assay, fluorescent-labelled cancer cells are
embedded between two layers of polymerised gel matrices.
The 3D ECM sandwich assay is ideal for long-term imaging.
This method can be performed in 96-well angiogenesis plates
consisting of two compartments: one with a smaller bottom
and a larger upper one. The bottom section is filled with an
ECM mixture, and after polymerization an ECM mixture
embedded with cells is added to the upper compartment.
In the upper compartment, a culture medium is added
prior to confocal fluorescence microscopy. This method is
ideal for visualization involving cells all located on one
level, unlike the case for hanging-drop aggregates. Our pre-
liminary data show that HSC-3 cells feature smaller nuclei
and move faster in Myogel–collagen (EH Apu 2015, unpub-
lished data) than in a Matrigelw collagen, and breast cancer
cells (MDA-MB-231) formed invasive properties in a
Myogel collagen (M Nees 2016, unpublished data).
(c) Tube formation assay using Myogel
In Myogel, a greater number of endothelial cells formed
along with smaller tubes compared with Matrigelw, which
is typically used for angiogenesis experiments. In both
matrices, the cellular network structures were fully devel-
oped by 12 h, but tube formation in Myogel continued for
as long as 72 h; at that time point in Matrigelw the endothelial
cells were already in apoptosis [85]. Therefore, vessel formation
assay in Myogel could be used for pro- or anti-angiogenic drug
assays where the number of tubes represents the most crucial
factor being evaluated.(d) Myogel in three-dimensional cancer drug testing
For cancer drug testing, a quantitative drug sensitivity score,
based on continuous modelling and integration of multiple
dose–response relationships in a high-throughput com-
pound test, was created [32]. Using this method, we tested
135 different drugs against pancreas carcinoma (Pa02c)
cells in 384 well plates, which were either uncoated or pre-
coated with Matrigelw or Myogel. Surprisingly, roughly
20% of the drugs yielded different results in the viability
test (ATP amount) when cells were cultured on coated
versus uncoated plates (K Tuomainen 2016, unpublished
data). These preliminary results suggest that cancer drugs
should be tested on cells cultured in contact with ECM
rather than simply on top of plastic.4. Conclusion
Myoma tissue products, created from leftover tumour pieces
following human uterus myoma removal, appear ethically
superior to sacrificing thousands of mice with basement
membrane–producing EHS tumours used to produce Matri-
gelw. Myoma discs and Myogel, the only available human
tumour-derived ECM products, appear completely suitable
for numerous solid cancer-related in vitro assays (migration,
invasion, radiation or drug testing). In future, we wish
that myoma discs and Myogel will ideally replace animal
tissue–derived matrices, such as Matrigelw and type I col-
lagen, for 3D experiments. In theory, Myogel and myoma
discs may well be used in future for ‘personalized medicine’
cancer assays.
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